KALA BIO Croissance future

Future contrôle des critères 0/6

Les bénéfices de KALA BIO devraient diminuer de 11.3% par an. Le BPA devrait augmenter de 46.9% par an.

Informations clés

-11.3%

Taux de croissance des bénéfices

46.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	37.3%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

LSE:0JQ2 - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	N/A	-45	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	2
9/30/2024	N/A	-39	N/A	N/A	N/A
6/30/2024	N/A	-39	-31	-31	N/A
3/31/2024	N/A	-40	-30	-29	N/A
12/31/2023	N/A	-42	-29	-28	N/A
9/30/2023	N/A	-46	-35	-34	N/A
6/30/2023	0	-9	-47	-47	N/A
3/31/2023	3	-26	-65	-65	N/A
12/31/2022	4	-45	-79	-79	N/A
9/30/2022	6	-80	-93	-93	N/A
6/30/2022	8	-137	-104	-103	N/A
3/31/2022	9	-145	-100	-100	N/A
12/31/2021	11	-143	-109	-108	N/A
9/30/2021	12	-126	-108	-106	N/A
6/30/2021	11	-126	-107	-106	N/A
3/31/2021	9	-113	-105	-103	N/A
12/31/2020	6	-104	-93	-91	N/A
9/30/2020	5	-95	-85	-83	N/A
6/30/2020	5	-90	-82	-80	N/A
3/31/2020	6	-91	-83	-81	N/A
12/31/2019	6	-94	-94	-93	N/A
9/30/2019	5	-98	-93	-90	N/A
6/30/2019	3	-90	-86	-84	N/A
3/31/2019	1	-81	-74	-73	N/A
12/31/2018	N/A	-67	-56	-54	N/A
9/30/2018	N/A	-53	-46	-45	N/A
6/30/2018	N/A	-47	N/A	-38	N/A
3/31/2018	N/A	-44	N/A	-37	N/A
12/31/2017	N/A	-42	N/A	-34	N/A
9/30/2017	N/A	-39	N/A	-35	N/A
6/30/2017	N/A	-39	N/A	-34	N/A
3/31/2017	N/A	-38	N/A	-32	N/A
12/31/2016	N/A	-33	N/A	-27	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-25	N/A	-19	N/A
3/31/2016	0	-18	N/A	-16	N/A
12/31/2015	0	-17	N/A	-15	N/A
9/30/2015	0	-17	N/A	-16	N/A
6/30/2015	0	-17	N/A	-17	N/A
3/31/2015	0	-18	N/A	-16	N/A
12/31/2014	0	-19	N/A	-15	N/A
12/31/2013	0	-11	N/A	-11	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 0JQ2 devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 0JQ2 devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 0JQ2 devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de 0JQ2 devraient croître plus rapidement que le marché UK.

Croissance élevée des revenus: 0JQ2 ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 0JQ2 devrait être élevé dans 3 ans

KALA BIO Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Recent updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance